<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>352</serviceExecutionTime><Drug id="42150"><DrugName>DTwP-Hep B-Hib vaccine, Crucell/Novartis</DrugName><DrugNamesKey><Name id="42843067">Quinvaxem</Name></DrugNamesKey><DrugSynonyms><Name><Value>DTPw-HBV-Hib vaccine, Berna/Chiron</Value></Name><Name><Value>DTP-HBV-Hib vaccine, Berna/Chiron</Value></Name><Name><Value>DTPw-HBV-Hib vaccine, Crucell/Chiron</Value></Name><Name><Value>DTP-HBV-Hib vaccine, Crucell/Chiron</Value></Name><Name><Value>Quinvaxem</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>DTPw-HepB-Hib</Value></Name><Name><Value>DTP-HBV-Hib vaccine, Berna/Novartis</Value></Name><Name><Value>DTP-HBV-Hib vaccine, Crucell/Novartis</Value></Name><Name><Value>DTPw-HBV-Hib vaccine, Berna/Novartis</Value></Name><Name><Value>DTPw-HBV-Hib vaccine, Crucell/Novartis</Value></Name><Name><Value>DTwP-Hep B-Hib vaccine, Crucell/Novartis</Value></Name><Name><Value>diphtheria/tetanus/pertussis/Haemophilus influenzae type B, hepatitis B pentavalent vaccine, Crucell/Novartis</Value></Name></DrugSynonyms><CompanyOriginator id="24766">Crucell Switzerland AG</CompanyOriginator><CompaniesPrimary><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Company id="24766">Crucell Switzerland AG</Company></CompaniesPrimary><CompaniesSecondary><Company id="15387">Chiron Vaccines Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="42150" type="Drug"><TargetEntity id="447284" type="siDrug">DTPw-HepB-Hib</TargetEntity></SourceEntity><SourceEntity id="1020606" type="Company"><TargetEntity id="4295905942" type="organizationId">Novartis Vaccines and Diagnostics Inc</TargetEntity></SourceEntity><SourceEntity id="15387" type="Company"><TargetEntity id="5000403716" type="organizationId">Chiron Vaccines Co</TargetEntity></SourceEntity><SourceEntity id="24766" type="Company"><TargetEntity id="4295890753" type="organizationId">Janssen Vaccines AG</TargetEntity></SourceEntity><SourceEntity id="145" type="ciIndication"><TargetEntity id="1410" type="siCondition"/></SourceEntity><SourceEntity id="152" type="ciIndication"><TargetEntity id="10019731" type="MEDDRA"/><TargetEntity id="D019694" type="MeSH"/><TargetEntity id="-1284790527" type="omicsDisease"/><TargetEntity id="429" type="siCondition"/></SourceEntity><SourceEntity id="47" type="ciIndication"><TargetEntity id="A37" type="ICD10"/><TargetEntity id="033" type="ICD9"/><TargetEntity id="10034738" type="MEDDRA"/><TargetEntity id="D014917" type="MeSH"/><TargetEntity id="1489" type="ORPHANET"/><TargetEntity id="-320620987" type="omicsDisease"/><TargetEntity id="2337" type="siCondition"/></SourceEntity><SourceEntity id="72" type="ciIndication"><TargetEntity id="10043376" type="MEDDRA"/><TargetEntity id="D013742" type="MeSH"/><TargetEntity id="3299" type="ORPHANET"/><TargetEntity id="-687302618" type="omicsDisease"/><TargetEntity id="816" type="siCondition"/></SourceEntity><SourceEntity id="81" type="ciIndication"><TargetEntity id="A36" type="ICD10"/><TargetEntity id="10013023" type="MEDDRA"/><TargetEntity id="D004165" type="MeSH"/><TargetEntity id="1679" type="ORPHANET"/><TargetEntity id="-360770994" type="omicsDisease"/><TargetEntity id="3234" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Bordetella pertussis infection - Ethiopia - Oct-2006</FirstLaunched><FirstLaunched>Bordetella pertussis infection - South Korea - Oct-2006</FirstLaunched><FirstLaunched>Clostridium tetani infection - Ethiopia - Oct-2006</FirstLaunched><FirstLaunched>Clostridium tetani infection - South Korea - Oct-2006</FirstLaunched><FirstLaunched>Corynebacterium diphtheriae infection - Ethiopia - Oct-2006</FirstLaunched><FirstLaunched>Corynebacterium diphtheriae infection - South Korea - Oct-2006</FirstLaunched><FirstLaunched>Haemophilus influenzae infection - Ethiopia - Oct-2006</FirstLaunched><FirstLaunched>Haemophilus influenzae infection - South Korea - Oct-2006</FirstLaunched><FirstLaunched>Hepatitis B virus infection - Ethiopia - Oct-2006</FirstLaunched><FirstLaunched>Hepatitis B virus infection - South Korea - Oct-2006</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="145">Haemophilus influenzae infection</Indication><Indication id="152">Hepatitis B virus infection</Indication><Indication id="47">Bordetella pertussis infection</Indication><Indication id="72">Clostridium tetani infection</Indication><Indication id="81">Corynebacterium diphtheriae infection</Indication></IndicationsPrimary><ActionsSecondary><Action id="12371">Subunit vaccine</Action><Action id="12375">Toxoid vaccine</Action><Action id="12378">Prophylactic vaccine</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2015-04-13T07:42:59.000Z</LastModificationDate><ChangeDateLast>2017-08-09T00:00:00.000Z</ChangeDateLast><AddedDate>2002-10-18T16:15:42.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="24766" linkType="Company"&gt;Berna Biotech&lt;/ulink&gt; (now &lt;ulink linkID="17254" linkType="Company"&gt;Crucell&lt;/ulink&gt;) and &lt;ulink linkID="1020606" linkType="Company"&gt;Novartis Vaccines &amp;amp; Diagnostics&lt;/ulink&gt; (now &lt;ulink linkID="28355" linkType="Company"&gt;GlaxoSmithKline&lt;/ulink&gt; following its acquisition of &lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt;' global vaccines business) have developed and launched Quinvaxem, an oral fully-liquid DTwP-Hep B-Hib pediatric vaccine, for the potential prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type B infection [&lt;ulink linkID="467199" linkType="reference"&gt;467199&lt;/ulink&gt;], [&lt;ulink linkID="467211" linkType="reference"&gt;467211&lt;/ulink&gt;], [&lt;ulink linkID="662631" linkType="Reference"&gt;662631&lt;/ulink&gt;], [&lt;ulink linkID="662678" linkType="Reference"&gt;662678&lt;/ulink&gt;]. In October 2006, the vaccine was launched in Korea [&lt;ulink linkID="765901" linkType="Reference"&gt;765901&lt;/ulink&gt;]. In August 2007, it was rolled out  in Ethiopia [&lt;ulink linkID="821958" linkType="Reference"&gt;821958&lt;/ulink&gt;]. By the end of 2007, it was being sold in many countries in South America and Africa and, by August 2008,  further rollout in other African and Asian countries  was underway [&lt;ulink linkID="943175" linkType="Reference"&gt;943175&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In August 2007, Crucell stated that the vaccine was rolled out  in Ethiopia [&lt;ulink linkID="821958" linkType="Reference"&gt;821958&lt;/ulink&gt;]. By the end of 2007, it was being sold in much of South America and eight countries in Africa and, by August 2008,  further rollout in other African and Asian countries  was underway [&lt;ulink linkID="943175" linkType="Reference"&gt;943175&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2006, Berna and Chiron submitted a registration dossier for the vaccine for routine pediatric vaccination to the licensing authorities in South Korea and the WHO. At that time, the companies expected to launch the vaccine in 2006 [&lt;ulink linkID="643853" linkType="Reference"&gt;643853&lt;/ulink&gt;]. In March 2006, the Korean FDA approved the vaccine [&lt;ulink linkID="658218" linkType="Reference"&gt;658218&lt;/ulink&gt;]; in October 2006, the vaccine was launched [&lt;ulink linkID="765901" linkType="Reference"&gt;765901&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By August 2004, DTPw-HBV-Hib was undergoing phase II trials and Berna was expecting a potential launch in 2005/2006 [&lt;ulink linkID="561226" linkType="Reference"&gt;561226&lt;/ulink&gt;], [&lt;ulink linkID="545354" linkType="Reference"&gt;545354&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Berna Biotech contributed the HBV component with &lt;ulink linkID="17493" linkType="Drug"&gt;Hepavax-Gene&lt;/ulink&gt;, while the remaining ingredients were provided by Chiron. The final formulation was to be done by the Berna Group in South Korea [&lt;ulink linkID="539129" linkType="Reference"&gt;539129&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006, Crucell was awarded 3-year contracts in excess of $230 million by supranational organizations for the use of DTPw-HBV-Hib and &lt;ulink linkID="17493" linkType="Drug"&gt;Hepavax-Gene&lt;/ulink&gt; in vaccination programs for the developing world [&lt;ulink linkID="747936" linkType="Reference"&gt;747936&lt;/ulink&gt;]. In September 2008, the company was awarded a further 3-year contract worth $140 million by supranational organizations for supplies of DTPw-HBV-Hib [&lt;ulink linkID="945323" linkType="Reference"&gt;945323&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="ET">Ethiopia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="ET">Ethiopia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="ET">Ethiopia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="ET">Ethiopia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="ET">Ethiopia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="XB">Africa South of the Sahara</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="XB">Africa South of the Sahara</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="ET">Ethiopia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="ET">Ethiopia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="XB">Africa South of the Sahara</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="XB">Africa South of the Sahara</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="XB">Africa South of the Sahara</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="XB">Africa South of the Sahara</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="ET">Ethiopia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="ET">Ethiopia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="XB">Africa South of the Sahara</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="XB">Africa South of the Sahara</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="XB">Africa South of the Sahara</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="ET">Ethiopia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="765901" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="XB">Africa South of the Sahara</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24766">Crucell Switzerland AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="943175" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2002-10-15T00:00:00.000Z</StatusDate><Source id="467211" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2002-10-15T00:00:00.000Z</StatusDate><Source id="467211" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2002-10-15T00:00:00.000Z</StatusDate><Source id="467211" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2002-10-15T00:00:00.000Z</StatusDate><Source id="467211" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2002-10-15T00:00:00.000Z</StatusDate><Source id="467211" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2002-10-15T00:00:00.000Z</StatusDate><Source id="467211" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2002-10-15T00:00:00.000Z</StatusDate><Source id="467211" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2002-10-15T00:00:00.000Z</StatusDate><Source id="467211" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2002-10-15T00:00:00.000Z</StatusDate><Source id="467211" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2006-01-05T00:00:00.000Z</StatusDate><Source id="643853" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2006-01-05T00:00:00.000Z</StatusDate><Source id="643853" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2006-01-05T00:00:00.000Z</StatusDate><Source id="643853" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2006-01-05T00:00:00.000Z</StatusDate><Source id="643853" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2006-01-05T00:00:00.000Z</StatusDate><Source id="643853" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2006-01-05T00:00:00.000Z</StatusDate><Source id="643853" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2006-01-05T00:00:00.000Z</StatusDate><Source id="643853" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2006-01-05T00:00:00.000Z</StatusDate><Source id="643853" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2006-01-05T00:00:00.000Z</StatusDate><Source id="643853" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2006-01-05T00:00:00.000Z</StatusDate><Source id="643853" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2004-08-31T00:00:00.000Z</StatusDate><Source id="561226" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2004-08-31T00:00:00.000Z</StatusDate><Source id="561226" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2004-08-31T00:00:00.000Z</StatusDate><Source id="561226" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2004-08-31T00:00:00.000Z</StatusDate><Source id="561226" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2004-08-31T00:00:00.000Z</StatusDate><Source id="561226" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2004-08-31T00:00:00.000Z</StatusDate><Source id="561226" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2004-08-31T00:00:00.000Z</StatusDate><Source id="561226" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2004-08-31T00:00:00.000Z</StatusDate><Source id="561226" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2004-08-31T00:00:00.000Z</StatusDate><Source id="561226" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2004-08-31T00:00:00.000Z</StatusDate><Source id="561226" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2006-03-27T00:00:00.000Z</StatusDate><Source id="658218" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2006-03-27T00:00:00.000Z</StatusDate><Source id="658218" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2006-03-27T00:00:00.000Z</StatusDate><Source id="658218" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2006-03-27T00:00:00.000Z</StatusDate><Source id="658218" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2006-03-27T00:00:00.000Z</StatusDate><Source id="658218" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="WO">World</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2005-09-30T00:00:00.000Z</StatusDate><Source id="658476" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="WO">World</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2005-09-30T00:00:00.000Z</StatusDate><Source id="658476" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="WO">World</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2005-09-30T00:00:00.000Z</StatusDate><Source id="658476" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="WO">World</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2005-09-30T00:00:00.000Z</StatusDate><Source id="658476" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24766">Crucell Switzerland AG</Company><Country id="WO">World</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2005-09-30T00:00:00.000Z</StatusDate><Source id="658476" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="WO">World</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2006-04-19T00:00:00.000Z</StatusDate><Source id="662678" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="WO">World</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2006-04-19T00:00:00.000Z</StatusDate><Source id="662678" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="WO">World</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2006-04-19T00:00:00.000Z</StatusDate><Source id="662678" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="WO">World</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2006-04-19T00:00:00.000Z</StatusDate><Source id="662678" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1020606">Novartis Vaccines &amp; Diagnostics</Company><Country id="WO">World</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2006-04-19T00:00:00.000Z</StatusDate><Source id="662678" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2006-03-27T00:00:00.000Z</StatusDate><Source id="658218" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2006-03-27T00:00:00.000Z</StatusDate><Source id="658218" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2006-03-27T00:00:00.000Z</StatusDate><Source id="658218" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2006-03-27T00:00:00.000Z</StatusDate><Source id="658218" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15387">Chiron Vaccines Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2006-03-27T00:00:00.000Z</StatusDate><Source id="658218" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1054027">United Nations International Children's Fund</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17332">Johnson &amp; Johnson</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><Deals><Deal id="117762" title="Crucell to receive funding for Hepavax-Gene and Quinvaxem vaccination programs for the developing world"/><Deal id="119638" title="Berna Biotech and Chiron Vaccines to codevelop DTPw-HBV-Hib hepatitis vaccine"/><Deal id="127641" title="Crucell to supply its Quinvaxem vaccine to undisclosed organization"/><Deal id="130408" title="Crucell to supply Quinvaxem to developing world under contract from UNICEF"/></Deals><PatentFamilies><PatentFamily id="1663509" number="WO-2008020322" title="Combination vaccines with 1-hydroxy-2-phenoxyethane preservative"/><PatentFamily id="1957031" number="WO-2006097851" title="Combination vaccines with whole cell pertussis antigen"/><PatentFamily id="2796635" number="WO-2014135651" title="Acellular pertussis vaccine"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Wurzburg" id="24121"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>